157 related articles for article (PubMed ID: 9808675)
1. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels.
Wang GW; Kang YJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):938-44. PubMed ID: 10027829
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes.
Wang GW; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2001 Aug; 298(2):461-8. PubMed ID: 11454906
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
[TBL] [Abstract][Full Text] [Related]
7. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
[TBL] [Abstract][Full Text] [Related]
8. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
10. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity.
Kang YJ; Chen Y; Yu A; Voss-McCowan M; Epstein PN
J Clin Invest; 1997 Sep; 100(6):1501-6. PubMed ID: 9294117
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
DiSilvestro RA; Liu J; Klaassen CD
Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
[TBL] [Abstract][Full Text] [Related]
14. Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells.
Paranka NS; Dorr RT
Anticancer Res; 1994; 14(5A):2047-52. PubMed ID: 7847848
[TBL] [Abstract][Full Text] [Related]
15. Effect of glutathione depletion by buthionine sulfoximine on doxorubicin toxicity in mice.
Kisara S; Furusawa S; Takayanagi Y; Sasaki K
Res Commun Mol Pathol Pharmacol; 1995 Sep; 89(3):401-10. PubMed ID: 8680808
[TBL] [Abstract][Full Text] [Related]
16. Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity.
Jing L; Wu Y; Wu J; Zhao J; Zuo D; Peng S
Eur J Pharmacol; 2011 Jun; 659(2-3):224-32. PubMed ID: 21463615
[TBL] [Abstract][Full Text] [Related]
17. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
18. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
19. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
20. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice.
Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S
Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
